Let us introduce you to some of the Cambridge Nutraceuticals Team.
If you're looking for vacancies in our team, please see our main jobs page on the FutureYou website.
Adam has extensive experience in small and medium companies and particularly ecommerce.
He has worked at Abcam, running the Business Intelligence and Opportunities department, managing teams of analysts and project managers. He also was Operations Director of Hubbub, an online food delivery business in London and worked as a management consultant for Newton Europe. He has held a non executive directorship at Bocca di Lupo, London’s acclaimed Italian restaurant, since it was founded. He holds an MEng in Engineering, Economics and Management from Oxford University.
Tim is a serial entrepreneur who has successfully built and sold businesses in several different sectors.
He was previously a non-executive director at Abcam plc, and prior to Abcam plc, he was Chief Executive and then Chairman of Ransom plc, which he built into one of the UK’s largest natural healthcare groups. He is an active angel investor and is a member of the Cambridge Angels investor group. Appointed as Cambridge Nutraceuticals’s interim CEO as part of the December 2012 financing round, in April 2015, on the appointment of Adam Cleevely as CEO, he took the role of Executive Chairman. He is also a trustee of the Whitley Fund for Nature. Tim is an Economics Exhibitioner and graduate of Cambridge University.
Head of Marketing
Chris has been involved with Ateronon from its early days. Chris has extensive experience in over the counter and generic pharmaceutical product management, as well as 3 years’ product marketing management with Lloyds Pharmacy.
Customer Services Manager
Nadia holds a first class degree in Medical Microbiology from the University of Surrey. Since graduating from university, Nadia has explored her love of science in a variety of companies including, a CRO, a biotechnology company and a medical communications agency.
Tim studied Mathematics at Cambridge University. Tim has extensive experience of both academic and more practical statistical & data analysis. Recently he worked at a large Cambridge biotech business to optimize stocking algorithms, identify customer needs and drive higher product quality.
Tudor joined in August 2016. He has extensive experience in web application development. Tudor has worked on web systems in diverse sectors including the US Health Insurance industry and fashion e-commerce.
Professor Alf Lindberg
A veteran scientist who was a former secretary of the Nobel Prize Committee for Physiology and Medicine, Dr Lindberg has also spent much of his career as a professor at Sweden’s prestigious Karolinska Institute in Stockholm.
Alf was also previously head of research at Wyeth and at Aventis. He now uses a lifetime of his own expertise and knowledge collected from years of contact with some of the world’s most respected minds, and travels the world as an advisor and consultant to a variety of big pharmaceutical and biotechnology companies.
Mr Peter Kirkpatrick
Peter Kirkpatrick is Ateronon’s key medical advisor. He is a senior specialist neurosurgeon at Addenbrooke’s Hospital, a world-class centre of medical expertise.
The hospital is affiliated to the University of Cambridge and makes up a part of the research-based Cambridge Bio-Medical Campus.
Mr Kirkpatrick is a leading expert on strokes and arterial and vascular disease affecting the brain, and has published more than 200 studies. He is also president of the Cambridgeshire branch of Headway, the brain injury charity, and has been a major fund-raiser for their work. His input into the analysis of research on Ateronon, and advice on future research priorities, is invaluable to the development of the business.
Mr Michael Heinrich
Michael Heinrich is a Professor of Ethnopharmacology and Medicinal Plant Research (Pharmacognosy) at University College London (‘UCL’) School of Pharmacy and was until recently the head of the research cluster there. He currently serves as the joint chair of UCL’s Research Ethics Committee.
Professor Heinrich is author of over 300 published peer-reviewed papers, and is widely cited and recognised as an expert in the field of medicinal plant research. His key areas of interest include the prevention and early stage management of diabetes (metabolic syndrome) and cancer chemoprevention based on the use of traditional medicines as well as best practice in the supply of herbal medical products / botanicals (value chains).